Friday, May 9, 2014

Should the Federal Government be able to stand in the way of Terminally Ill Patients seeking Experimental Drugs?

Should people fighting for their lives have to battle red tape? 
That’s the question lawmakers are considering in four states where the “Right to Try” act is moving forward – proposed legislation aimed at giving terminally ill people access to experimental, but potentially life-saving, drugs before they have FDA approval.
Americans like Keith Knapp, of California, have fought hard for this kind of legislation. 
Keith Knapp married his high school sweetheart Mikaela. He and Mikaela thought they had their whole lives ahead of them --- until last year, when she was diagnosed with a terminal form of kidney cancer. This began a fight that the two of them never imagined, as they tried to gain access to a promising, but not-yet-FDA-approved, drug that was doing well in clinical trials. The couple learned that without being in one of these trials, current law would not allow them access to the experimental treatment.
From her hospital bed, Mikaela said recently: “People die from not being able to access these drugs all the time. I don't want to be one of them.” 
But sadly, she was. Despite her husband’s passionate efforts to lobby members of Congress, pharmaceutical companies and the FDA -- and a huge media campaign -- Mikaela lost her battle just two weeks ago.
“The amount of effort you have to put into doing this is just far too much at this time in our life when you really just want to slow things down and enjoy being together,” Keith said. 
Currently, it takes the FDA about 10 years to complete a clinical trial on a new drug -- and while many try, only 3 percent will gain access to a trial during that time. Meanwhile, 500,000 Americans died last year from cancer alone, with thousands more dying of other illnesses.
Read the rest of the story HERE and view a related video below:



If you like what you see, please "Like" us on Facebook either here or here. Please follow us on Twitter here.


No comments: